Treatment

Resmetirom and Advanced Liver Fibrosis

Resmetirom (MGL-3196) received accelerated FDA approval in March 2024 for treating MASH with moderate to advanced liver fibrosis (F2-F3). This approval followed the MAESTRO-NASH trial, which showed significant...

Corrie Berk,

DNP, MBA, APRN
Nurse Practitioner, Texas Liver Institute

Resmetirom FDA-Approved for MASH

In 2024, resmetirom (MGL-3196) became the first FDA-approved drug for MASH, demonstrating significant efficacy in resolving MASH without worsening fibrosis...

CURATED BY:
Corrie Berk,
DNP, MBA, APRN

MASEF Score Promising for Early Detection of At-Risk MASH, Non-Invasive Alternative to VCTE

Early identification of patients with a NAFLD activity score ≥4 and significant fibrosis (≥F2) is crucial, as these individuals are...

CURATED BY:
Corrie Berk,
DNP, MBA, APRN

Top Therapies for Reducing Hepatic Fat in MASH Identified in Meta-Analysis

Metabolic dysfunction–associated steatohepatitis (MASH) is a major contributor to liver disease, and reducing hepatic fat is critical for improving patient...

CURATED BY:
Corrie Berk,
DNP, MBA, APRN

A Growing Liver Disease Linked to Metabolic Imbalances, Inflammation

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world, affecting around 30% of...

CURATED BY:
Chantil D. Jeffreys,
FNP, DNP, JD

Obesity Fuels Rise in Nonalcoholic Fatty Liver Disease

The rise in obesity has led to increased metabolic diseases like insulin resistance, type 2 diabetes, and nonalcoholic fatty liver...

CURATED BY:
Miu Lai (Milly) Ng,
FNP-BC, MPH (Harvard)

NAFLD: Rising Global Health Issue Tied to Metabolic Dysfunction, Gut Microbiome, and Emerging Therapies

Non-alcoholic fatty liver disease (NAFLD) is characterized by ≥5% hepatic steatosis unrelated to alcohol or drug use, primarily driven by...

CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

Company
Contact

Partner with Us
Ambassador Program

Treatment

Resmetirom and Advanced Liver Fibrosis

Corrie Berk,

Resmetirom FDA-Approved for MASH

MASEF Score Promising for Early Detection of At-Risk MASH, Non-Invasive Alternative to VCTE

Top Therapies for Reducing Hepatic Fat in MASH Identified in Meta-Analysis

A Growing Liver Disease Linked to Metabolic Imbalances, Inflammation

Obesity Fuels Rise in Nonalcoholic Fatty Liver Disease

NAFLD: Rising Global Health Issue Tied to Metabolic Dysfunction, Gut Microbiome, and Emerging Therapies

© 2025 Point of Care Network, LLC. All Rights Reserved.

© 2025 Point of Care Network, LLC. All Rights Reserved.

Share